Volume 36, Issue 261 (10-2026)
J Mazandaran Univ Med Sci 2026, 36(261): 144-150 |
Back to browse issues page
Download citation:
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:
Mesgar A H, Baghbanian S M, Ghazaeian M. Factors Associated with COVID-19 Infection and Hospitalisation among Patients with Multiple Sclerosis in Mazandaran: A Short Report. J Mazandaran Univ Med Sci 2026; 36 (261) :144-150
URL: http://jmums.mazums.ac.ir/article-1-22666-en.html
URL: http://jmums.mazums.ac.ir/article-1-22666-en.html
Abstract: (27 Views)
Background and purpose: Given the high mortality associated with COVID-19 infection, this study aimed to investigate the clinical outcomes of COVID-19 infection in patients with multiple sclerosis (MS).
Materials and methods: Patients who provided a response during the initial history-taking process between February 2020 and February 2021 were included in the study. All adult patients with MS aged 18 years or older were identified using census sampling. Demographic characteristics, underlying medical conditions, medications, and clinical manifestations were recorded. Information on patients hospitalised at the medical centre was obtained from electronic medical records. A p-value of less than 0.05 was considered statistically significant.
Results: The study included 618 patients with MS from Mazandaran Province. The incidence of COVID-19 infection was higher among women than men. No significant associations were found between hospitalisation and factors such as mean body mass index (BMI), use of MS immunomodulatory medications, or other clinical symptoms. Furthermore, no significant difference was observed in pre-COVID-19 scores on the Expanded Disability Status Scale (EDSS) between hospitalised and non-hospitalised patients.
Conclusion: Female sex and hypertension were associated with an increased risk of COVID-19 infection among patients with MS. No clear association was observed between the specific types of immunomodulatory medications used to treat MS and the occurrence of COVID-19 in this population. These findings may help inform preventive strategies and vaccination prioritisation for this potentially vulnerable population. Prospective studies with larger sample sizes are recommended to confirm these findings.
Materials and methods: Patients who provided a response during the initial history-taking process between February 2020 and February 2021 were included in the study. All adult patients with MS aged 18 years or older were identified using census sampling. Demographic characteristics, underlying medical conditions, medications, and clinical manifestations were recorded. Information on patients hospitalised at the medical centre was obtained from electronic medical records. A p-value of less than 0.05 was considered statistically significant.
Results: The study included 618 patients with MS from Mazandaran Province. The incidence of COVID-19 infection was higher among women than men. No significant associations were found between hospitalisation and factors such as mean body mass index (BMI), use of MS immunomodulatory medications, or other clinical symptoms. Furthermore, no significant difference was observed in pre-COVID-19 scores on the Expanded Disability Status Scale (EDSS) between hospitalised and non-hospitalised patients.
Conclusion: Female sex and hypertension were associated with an increased risk of COVID-19 infection among patients with MS. No clear association was observed between the specific types of immunomodulatory medications used to treat MS and the occurrence of COVID-19 in this population. These findings may help inform preventive strategies and vaccination prioritisation for this potentially vulnerable population. Prospective studies with larger sample sizes are recommended to confirm these findings.
Type of Study: Brief Report |
Subject:
Neurology
Send email to the article author
| Rights and permissions | |
 |
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License. |
Articles Copyright © The Author(s). Owned by Mazandaran University of Medical Sciences.
Contact Us
Address: Journal Office, Building No. 2, Mazandaran University of Medical Sciences, Moallem Square, Sari.Tel: +98 (011)34484874 Postal code: 48175-866 E-Mail: jmums@mazums.ac.ir Telefax: +98 (011)33262679
